Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2023.1218427 Immunology Correction Corrigendum: Concurrent IgA nephropathy and membranous nephropathy, is it an overlap syndrome? He Jia-Wei 1 † Cui Dong-Feng 2 † Zhou Xu-Jie 1 * Chen Pei 1 Li Yang 1 Zhang Xue 1 Wang Yan-Na 1 Gan Ting 1 Liu Li-Jun 1 Shi Su-Fang 1 Zhu Li 1 Hou Ping 1 Lv Ji-Cheng 1 Zhang Hong 1 * 1 Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China 2 Renal Division, The Third People’s Hospital of Zhengzhou, Zhengzhou, China

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: Xu-Jie Zhou, zhouxujie@bjmu.edu.cn; Hong Zhang, hongzh@bjmu.edu.cn

†These authors have contributed equally to this work and share first authorship

 09 06 2023 2023 14 1218427 07 05 2023 30 05 2023 Copyright © 2023 He, Cui, Zhou, Chen, Li, Zhang, Wang, Gan, Liu, Shi, Zhu, Hou, Lv and Zhang 2023 He, Cui, Zhou, Chen, Li, Zhang, Wang, Gan, Liu, Shi, Zhu, Hou, Lv and Zhang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A corrigendum on Concurrent IgA nephropathy and membranous nephropathy, is it an overlap syndrome? by He J-W, Cui D-F, Zhou X-J, Chen P, Li Y, Zhang X, Wang Y-N, Gan T, Liu L-J, Shi S-F, Zhu L, Hou P, Lv J-C and Zhang H (2022) Front. Immunol. 13:846323. doi: 10.3389/fimmu.2022.846323 IgA nephropathy primary membranous nephropathy galactose-deficient IgA1 anti-phospholipase A2 receptor polygenic risk score section-in-acceptance Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

In the published article, there was an error in the legend for Figure 5 as published. Part (A) incorrectly read “The comparison of the total-average proteinuria” instead of “The comparison of the time-average proteinuria”. The corrected legend appears below.

(A) The comparison of the time-average proteinuria among patients with IgAN, cIgAN/MN and MN. (B) Proteinuria persisted means patients could not achieve complete or partial proteinuria remission during follow-up, which was were calculated according to the Kaplan-Meier method (log-rank test). ns, not significant.

In the published article, there was also a word expression error.

A correction has been made to Results, Follow-Up Evaluation, paragraph number 4. This sentence previously stated:

“Compared to IgAN, the cumulative incidence of persistent proteinuria after therapy in patients with cIgAN/MN was lower than in IgAN (P=0.001).”

The corrected sentence appears below:

“Compared to IgAN, the cumulative incidence of persistent proteinuria after therapy in patients with cIgAN/MN was higher than in IgAN (P=0.001).”

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.